1176 Optimal Timing of PD-1 Inhibitor Immunotherapy Administration to Stereotactic Radiosurgery in Malignant Gliomas: A Propensity-Matched Multi-Institutional Cohort Study

View at publisher Summarise with VIRAT
Authors: Sean O’Leary, Allen Ye Fu, Vaughn A. Rogers, Blake Perdikis, Michael Farid, Kwadwo Darko, Hammad A. Khan, Umaru Barrie
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: The optimal order of treatment with PD-1 inhibitor immunotherapy and stereotactic radiosurgery (SRS) in malignant gliomas remains unclear. METHODS: A retrospective analysis was conducted using the TriNetX Research Network (2005–2022), identifying adults with malignant gliomas who received SRS and at least one PD-1 inhibitor. Patients were stratified into two cohorts based on whether PD-1 inhibition occurred 8 weeks before (pre-SRS) versus after SRS (post-SRS). Propensity score matching (1:1) was performed for demographics, comorbidities, and relevant medications. Clinical outcomes—mortality, cognitive impairment, cranial nerve deficits, seizures, hemorrhagic complications, and functional impairments—were assessed over a 3-year follow-up. Odds ratios (OR) with 95% confidence intervals (CI) were calculated, and Kaplan-Meier survival analyses were used to compare cumulative incidence rates. RESULTS: Before matching, pre-SRS (n = 429) vs. after (n = 381) post-SRS differed significantly in sex (female), ethnicity (Hispanic), race (Asian, American Indian), overweight/obesity, type 2 diabetes, lipidemia, and anticoagulant use (p < 0.05). After propensity score matching (n = 233 per group), pre-SRS vs. post-SRS showed no significant differences in baseline characteristics, except for age (63.50 ± 11.84 vs. 63.36 ± 10.82, p = 0.012) and atezolizumab use (0 (0.00%) vs. ≤ 10 (≤4.29%), p = 0.001). in propensity score–matched patients, PD-1 inhibitor use before was associated with significantly higher odds of cognitive impairments (OR 1.75, 95% CI 1.04–2.98, p = 0.034), cranial nerve deficits (OR 2.00, 95% CI 1.11–3.69, p = 0.021), and mortality (OR 1.53, 95% CI 1.06–2.20, p = 0.023), while other outcomes—including behavioral/mood changes (OR 0.91, p = 0.726), gait/coordination disorders (OR 1.28, p = 0.421), hemorrhagic complications (OR 0.97, p = 0.930), motor deficits (OR 0.86, p = 0.590), seizures/epilepsy (OR 0.99, p = 0.971), and sensory disturbances (OR 0.91, p = 0.737)—showed no significant differences. Kaplan-Meier analyses confirmed elevated risks of cognitive impairment (p = 0.0076), cranial nerve deficits (p = 0.0104), and mortality (p = 0.0109) in the pre-SRS group. CONCLUSIONS: Pre-SRS PD-1 use was associated with more neurological deficits and lower survival, highlighting the need for prospective studies on optimal SRS-immunotherapy timing in malignant gliomas.

Fields of Study & Subjects

Glioma Diagnosis and Treatment Cancer Immunotherapy and Biomarkers Brain Metastases and Treatment

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
228–229
Publication date
26 March 2026
Language
EN